Zimmer Biomet Holdings, Inc. $ZBH Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,224,163 shares of the medical equipment provider’s stock after acquiring an additional 24,208 shares during the quarter. Dimensional Fund Advisors LP’s holdings in Zimmer Biomet were worth $201,082,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the business. DV Equities LLC acquired a new position in Zimmer Biomet in the fourth quarter worth approximately $25,000. Monetary Solutions Ltd acquired a new stake in shares of Zimmer Biomet during the 4th quarter valued at $30,000. Gen Wealth Partners Inc bought a new stake in shares of Zimmer Biomet during the 4th quarter worth $31,000. Flagship Harbor Advisors LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter worth $32,000. Finally, Headlands Technologies LLC acquired a new position in shares of Zimmer Biomet in the 2nd quarter worth $37,000. Institutional investors own 88.89% of the company’s stock.

Insider Buying and Selling at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares in the company, valued at approximately $2,252,022.64. The trade was a 15.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.28% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the stock. Truist Financial reaffirmed a “hold” rating and set a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Leerink Partners began coverage on shares of Zimmer Biomet in a report on Monday, April 13th. They set a “hold” rating and a $101.00 price target on the stock. Citizens Jmp reduced their price target on shares of Zimmer Biomet from $120.00 to $105.00 and set a “market outperform” rating for the company in a research report on Wednesday, April 29th. Canaccord Genuity Group set a $83.00 price objective on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Finally, Stifel Nicolaus reduced their target price on Zimmer Biomet from $110.00 to $105.00 and set a “buy” rating for the company in a report on Wednesday, April 29th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $100.70.

Zimmer Biomet Trading Up 1.9%

NYSE ZBH opened at $91.35 on Friday. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $108.29. The firm’s fifty day simple moving average is $87.90 and its 200-day simple moving average is $89.81. The company has a market capitalization of $17.67 billion, a PE ratio of 23.73, a price-to-earnings-growth ratio of 2.64 and a beta of 0.46.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 EPS for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The firm had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm’s revenue was up 9.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.81 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.48 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio is currently 24.94%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.